Cargando…

Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosis

One of the first targets proposed as an anti-fibrotic therapy was CCN2. Proof of its involvement in fibrosis was initially difficult, due to the lack of appropriate reagents and general understanding of the molecular mechanisms responsible for persistent fibrosis. As these issues have been progressi...

Descripción completa

Detalles Bibliográficos
Autor principal: Leask, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511481/
https://www.ncbi.nlm.nih.gov/pubmed/32410169
http://dx.doi.org/10.1007/s12079-020-00568-1